| Literature DB >> 35905216 |
Wannaporn Tianthong1, Orapan Aryasit.
Abstract
To evaluate the surgical outcomes and complications of evisceration or enucleation with primary implantation, performed by ophthalmology resident trainees, in regards to patients with recalcitrant endophthalmitis or panophthalmitis. We also compared the surgical outcomes and complications between resident trainees and experienced staff. In this retrospective analysis, the clinical records of all patients diagnosed with endophthalmitis or panophthalmitis who underwent enucleation or evisceration with primary implantation over a 13-year period were reviewed. The factors predicting implant exposure or extrusion in regards to patients who underwent eye removal by trainees were identified using multivariate analysis. The percentages of successful prosthesis fittings and complications were also reported. Sixty-six patient records, median age of 46.8 years, who underwent eye removal by resident trainees were reviewed. Thirty-six (55%) out of 66 patients were diagnosed with panophthalmitis. Four patients (6%) had implant exposure, and 4 patients (6%) had implant extrusion. Multivariate analysis demonstrated that Pseudomonas aeruginosa infection (P = .02, adjusted odd ratio [aOR] = 33.75) and not receiving intravitreal antimicrobial drugs before the eye removal procedure (P = .02, aOR = 30.11) were associated with implant exposure or extrusion. Patients with panophthalmitis who underwent evisceration had a higher rate of implant exposure or extrusion than those who underwent enucleation (P = .03, aOR 38.38). At the last visit, 65 patients had a successful prosthesis fitting. Furthermore, there were similar rates of complications and successful prosthesis fittings between experienced staff and resident trainees. This study suggests that evisceration or enucleation with primary implant placement in patients with recalcitrant endophthalmitis or panophthalmitis can be performed by resident trainees with acceptable surgical outcomes and a low rate of serious complications.Entities:
Mesh:
Year: 2022 PMID: 35905216 PMCID: PMC9333489 DOI: 10.1097/MD.0000000000029932
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1.Flow diagram of patient enrollment.
Complications of evisceration or enucleation with primary implant placement in patients with recalcitrant endophthalmitis or panophthalmitis.
|
|
|
|
|
|---|---|---|---|
| Severe complications, n (%) | |||
| Implant exposure or extrusion | 8 (12) | 1 (13) | 1.00 |
| Wound dehiscence | 3 (5) | 1 (13) | .37 |
| Minor complications, n (%) | |||
| Infected socket | 14 (21) | 2 (25) | 1.00 |
| Lower lid laxity | 5 (8) | 1 (13) | .51 |
| Late orbital cellulitis | 2 (3) | 0 (0) | 1.00 |
| Ptosis | 0 (0) | 1 (13) | .11 |
Univariate analysis for factors related to implant exposure or extrusion.
|
|
|
|
| ||
|---|---|---|---|---|---|
| Age (yr) | |||||
| Mean (SD) | 44.7 (21.2) | 41.6 (19.2) | .42 | ||
| Median (min–max) | 48.1 (3.9–84.1) | 34.9 (22.8–83.8) | |||
| Age (yr) | |||||
| >46.8 | 30 (51.7) | 2 (25.0) | .26 | 1 | |
| ≤46.8 | 28 (48.3) | 6 (75.0) | 3.21 (0.60–17.27) | .17 | |
| Gender | |||||
| Male | 38 (65.5) | 5 (62.5) | 1.00 | 1 | |
| Female | 20 (34.5) | 3 (37.5) | 1.14 (0.25–5.27) | .87 | |
| Diagnosis of affected eye | |||||
| Endophthalmitis | 27 (46.6) | 3 (37.5) | .72 | 1 | |
| Panophthalmitis | 31 (53.4) | 5 (62.5) | 1.45 (0.32–6.65) | .63 | |
| Cause of endophthalmitis or panophthalmitis | |||||
| Trauma | 32 (55.2) | 4 (50.0) | .97 | 1 | |
| Endogenous | 9 (15.5) | 1 (12.5) | 0.89 (0.09–8.98) | .92 | |
| Postoperation | 6 (10.3) | 1 (12.5) | 1.33 (0.13–14.10) | .81 | |
| Others | 11 (18.9) | 2 (25.0) | 1.45 (0.23–9.07) | .69 | |
| Cause of endophthalmitis or panophthalmitis | |||||
| Trauma | 32 (55.2) | 4 (50.0) | 1.00 | 1 | |
| Nontrauma | 26 (44.8) | 4 (50.0) | 1.23 (0.28–5.40) | .78 | |
| Preoperative visual acuity | |||||
| Better than HM | 1 (1.8) | 0 (0.0) | 1 | ||
| HM or worse | 56 (98.2) | 8 (100.0) | 1 (omitted) | – | |
| Types of operation | |||||
| Enucleation | 49 (84.5) | 4 (50.0) | .04 | 1 | |
| Evisceration | 9 (15.5) | 4 (50.0) | 5.44 (1.15–25.85) | .03 | |
| Diagnosis of affected eye and eye removal procedure | |||||
| Panophthalmitis and enucleation | 30 (51.7) | 3 (37.5) | 1 | ||
| Endophthalmitis and enucleation | 19 (32.7) | 1 (12.5) | .01 | 0.53 (0.06–5.44) | .59 |
| Endophthalmitis and evisceration | 8 (13.8) | 2 (25.0) | 2.5 (0.36–17.60) | .36 | |
| Panophthalmitis and evisceration | 1 (1.7) | 2 (25.0) | 20.0 (1.37–291.07) | .03 | |
| No | 45 (77.6) | 7 (87.5) | 1.00 | 1 | |
| Yes | 13 (22.4) | 1 (12.5) | 0.49 (0.06–4.39) | .53 | |
|
| |||||
| No | 55 (94.8) | 6 (75.0) | .11 | 1 | |
| Yes | 3 (5.2) | 2 (25.0) | 6.11 (0.85–44.16) | .07 | |
| Underlying diseases | |||||
| No | 35 (60.3) | 4 (50.0) | .71 | 1 | |
| Yes | 23 (39.7) | 4 (50.0) | 1.52 (0.35–6.70) | .58 | |
| White blood cell count (cells/µL) | |||||
| ≤9500 | 11 (19.0) | 1 (12.5) | 1.00 | 1 | |
| >9500 | 47 (81.0) | 7 (87.5) | 1.64 (0.18–14.72) | .70 | |
| Intravitreal antimicrobial drugs | |||||
| Yes | 40 (69.0) | 2 (25.0) | .02 | 1 | |
| No | 18 (31.0) | 6 (75.0) | 6.67 (1.22–36.28) | .03 | |
| Intravenous antimicrobial drugs | |||||
| No | 2 (3.5) | 1 (12.5) | .33 | 1 | |
| Yes | 56 (96.5) | 7 (87.5) | 0.25 (0.02–3.13) | .28 | |
| Prior ocular surgery | |||||
| No | 14 (24.1) | 4 (50.0) | .20 | 1 | |
| Yes | 44 (75.9) | 4 (50.0) | 0.32 (0.07–1.44) | .14 | |
| Type of orbital implant | |||||
| Nonporous | 56 (96.6) | 8 (100.0) | 1.00 | 1 | |
| Porous | 2 (3.4) | 0 (0.0) | 1 (omitted) | – | |
| Implant size (mm) | |||||
| 14–18 | 21 (36.2) | 1 (12.5) | .25 | 1 | |
| 20 | 37 (63.8) | 7 (87.5) | 3.97 (0.46–35.54) | .21 | |
Multivariate analysis for factors related to implant exposure or extrusion.
|
|
| |
|---|---|---|
| Age (yr) | ||
| ≥46.8 | 1 | |
| <46.8 | 7.65 (0.64–90.88) | .11 |
|
| ||
| No | 1 | |
| Yes | 33.75 (1.72–663.73) | .02 |
| Diagnosis of affected eye and eye removal procedure | ||
| Panophthalmitis and enucleation | 1 | |
| Panophthalmitis and evisceration | 38.38 (1.39–1059.24) | .03 |
| Intravitreal antimicrobial drugs | ||
| Yes | 1 | |
| No | 30.11 (1.64–552.25) | .02 |